8. November 2011
Download press release here (german).

The  company  JenLab  GmbH,  pioneer  of  the  multiphoton  tomograph,  releases  a  further innovative  product:  the  multiphoton  laser  microscope  2PM!.  The  ultracompact  low-cost femtosecond  laser  microscope  provides  high-resolution  two-photon  images.  Furthermore,  it can be used for precise nanosurgery. Major applications iinclude 3D imaging of living cells, the  optical  cleaning  of  stem  cell  cultures  as  well  as  the  patented  femtosecond  laser transfection.    

Download press release here (0,4 MB)

The  novel  laser  tomograph  MPTflex!  will  be  demonstrated  during  the  medica.  The tomograph  provides  a  spectacular  precise  view  into  the  skin.  The  tight  focused  beam  of  a femtosecond laser scans the skin within a few minutes and depicts the living skin cells onto the  screen.  Single  cancer  cells  can  be  monitored  without  any  physical  taken  biopsies  and without  any  staining.  Furthermore,  the  skin  age  can  be  determined  and  the  efficacy  of  anti-ageing-products  can  be  evaluated.    The  laser  tomograph  is  based  on  the  detection  of  the fluorescence of light-emitting endogenous biomolecules.   The  laser tomograph  MPTflex™  was  developed  from  JenLab  GmbH  in  its  facilities  in Saarbruecken  and  Jena.  It  is  currently  in  operation  in  California,  Mannheim/Germany,  and Vienna.  At  Irvine,  researchers  develop  a  fast  method  on  fast  melanoma  diagnosis  whereas biologists  at  San  Diego  employ  the  system  to  track  stem  cells  in  hair  follicles.  The dermatologists in Mannheim use the tomograph to optimize the treatment of chronic wounds. Scientists at  Vienna  perform  comparative  studies  with  other  imaging  tools.  In  Japan  starts  a study on the biosafety of sunscreen nanoparticles and the effect of anti-ageing lotions within the next weeks.   The  novel  multiphoton  tomograph  MPTflex!  was  awarded  with  the  Oscar  of  Photonics as most innovative Life sciences product in San Francisco this year. According to Dr. Karsten König,  CEO  of  the  German  company  JenLab  GmbH,  the  tomograph  MPTflex!  is  the imaging system with the best resolution so far. About a factor of 100 better than ultrasound. Even  small  organelles  such  as  mitochondria  as  well  as  single  elastin  fibers  and  collagen structures can be depicted in three dimensions on the computer screen. The  multiphoton  tomograph  has  the  potential  to  reduce  the  number  of  skin  biopsies  in hospitals  significantly.  And  it  is  possible  to  evaluate  exactly  the  effect  of  anti-ageing products. The precise view under the skin becomes reality. 

Download press release here (0,2 MB) 

Innovation: Multiphoton Tomograph for the Detection of Melanoma and Other Skin Diseases Issue 13, April 2011

The clinical tomograph MPTflex™, which was developed by the German university spin-off Jenlab GmbH, is a novel skin imaging device that overcomes the poor resolution of skin imaging methods such as ultrasound, optical coherence tomography (OCT) and reflection. By using twophoton technology, the system's high-resolution skin imaging provides marker-free optical biopsies. The awardwinning tomograph is a compact system, with a flexible scan head that includes two detectors for simultaneous measurement of autofluorescence and the secondharmonic generation, used mainly for the early detection of melanoma and diagnostics of dermatological disorders. Providing a fast microscopic view into the skin without any surgery, single cancer cells, as well as elastin fibers and nanoparticles can be imaged in vivo, and skin aging can be measured. The MPTflex™ tomograph is based on the twophoton effects predicted by the 1963 German-American Nobel Prize laureate Maria Goeppert-Mayer. The MPTflex™ received the 2011 Prism Award for Photonics Innovation in January. Co-founded in 1999 by Prof. Dr. Karsten König, Jenlab's primary goals are the development and the establishment of innovative bioinstrumentation based on Femtosecond Laser Technology for biotechnology, cell biology and medicine. More than 2,000 patients have already been investigated at clinics in Irvine, Brisbane, London, Modena, and Berlin. In the U.S., first clinical trials have been conducted at the University of California this year. For more information, please click here.
source: www.germaninnovation.org/research-and-innovation/centers-of-innovation-in-germany/german-innovations

Download press release here (0,4 MB)

Download press release here (0,3 MB) 

see also: www.electrooptics.com